Author: "Lee, Fa Chyi" / Topic: health - Searchworks@Jio Institute Digital Library Search Results

Author: Lenz, Heinz-Joseph, Lee, Fa-Chyi, Haller, Daniel G., Singh, Deepti, Benson, Al B., III, Strumberg, Dirk, Yanagihara, Ronald, Yao, James C., Phan, Alexandra T., and Ajani, Jaffer A.
Subjects: Stomach cancer -- Care and treatment, Stomach cancer -- Development and progression, Stomach cancer -- Research, Cisplatin -- Research, Health
Published: 2007

Author: Lee, Fa Chyi, Parasher, Gulshan, Roach, Mary, Hunt, Curtis, and Heywood, Glenroy
Subjects: Capecitabine -- Dosage and administration, Celecoxib -- Dosage and administration, Drug therapy, Combination -- Methods, Cancer -- Care and treatment, Cancer -- Methods, Health
Abstract: Abstract Background: Patients with metastatic biliary cancers continue to face a very grim prognosis with no effective chemotherapy. Median survival is around 6-9 months. Irinotecan and capecitabine have modest activity [...]
Published: 2007

Author: Rabinowitz, Max, Mangalik, Aroop, Lee, Fa-Chyi, Jennings, Carla, Parsons, Ann, Verschraegen, Claire, Royce, Melanie, and Rabinowitz, Ian
Subjects: Breast cancer -- Drug therapy, Metastasis -- Drug therapy, Carboplatin -- Dosage and administration, Capecitabine -- Dosage and administration, Drug therapy, Combination -- Methods, Cancer -- Care and treatment, Cancer -- Research, Health
Abstract: Abstract Most patients with breast cancer receive anthracyclines and taxanes in either the adjuvant or metastatic setting. Carboplatin, vinorelbine and capecitabine each has single agent activity in breast cancer. In [...]
Published: 2007

Author: Lee, Fa Chyi, Parasher, Gulshan, Roach, Mary, Hunt, Curtis, and Heywood, Glenroy
Subjects: Capecitabine -- Dosage and administration, Capecitabine -- Influence, Celecoxib -- Dosage and administration, Celecoxib -- Influence, Drug therapy, Combination -- Research, Drug targeting -- Methods, Cancer -- Care and treatment, Cancer -- Research, Health
Abstract: Abstract Background: Patients with metastatic biliary cancers continue to face a very grim prognosis with no effective chemotherapy. Median survival is around 6-9 months. Irinotecan and capecitabine have modest activity [...]
Published: 2007

Author: Rabinowitz, Max, Mangalik, Aroop, Lee, Fa-Chyi, Jennings, Carla, Parsons, Ann, Verschraegen, Claire, Royce, Melanie, and Rabinowitz, Ian
Subjects: Breast cancer -- Care and treatment, Breast cancer -- Complications and side effects, Breast cancer -- Analysis, Cancer patients -- Care and treatment, Cancer patients -- Analysis, Oncology, Experimental -- Complications and side effects, Oncology, Experimental -- Analysis, Chemotherapy -- Analysis, Radiotherapy -- Analysis, Drug therapy, Combination -- Analysis, Lung cancer, Non-small cell -- Care and treatment, Lung cancer, Non-small cell -- Complications and side effects, Lung cancer, Non-small cell -- Analysis, Growth factors -- Complications and side effects, Growth factors -- Analysis, Metastasis -- Care and treatment, Metastasis -- Complications and side effects, Metastasis -- Analysis, Cancer -- Research, Cancer -- Complications and side effects, Cancer -- Analysis, Cancer -- Chemotherapy, Health
Abstract: Abstract Most patients with breast cancer receive anthracyclines and taxanes in either the adjuvant or metastatic setting. Carboplatin, vinorelbine and capecitabine each has single agent activity in breast cancer. In [...]
Published: 2007

Searchworks